Pulmonary emphysema is not the same as COPD, but it is one of the main conditions that falls under the COPD umbrella. COPD, or chronic obstructive pulmonary disease, is a broad term covering lung diseases that progressively restrict airflow. Emphysema is one of the most common types, alongside chronic bronchitis. Many people have features of both at the same time, which is part of why the two terms get confused.
How COPD and Emphysema Are Related
Think of COPD as a category and emphysema as one item in that category. A COPD diagnosis means your lungs have permanent airflow limitation, confirmed by a breathing test called spirometry. The specific test result that clinicians look for is a ratio of how much air you can force out in one second compared to your total forced breath. When that ratio falls below 0.7, it points to COPD.
What COPD doesn’t tell you is exactly what’s happening inside your lungs. Two people can have the same spirometry numbers but very different underlying problems. One might have mostly emphysema, where the tiny air sacs are being destroyed. Another might have mostly chronic bronchitis, where the airways are inflamed and producing excess mucus. A third might have significant amounts of both. The COPD label groups all of these together because the treatments and monitoring overlap, but the biology is distinct.
What Emphysema Does to Your Lungs
Your lungs contain roughly 300 million tiny air sacs called alveoli. These sacs are where oxygen passes into your blood and carbon dioxide passes out. They’re surrounded by a network of elastic fibers that stretch when you breathe in and snap back when you breathe out, providing the force that pushes air out of your lungs.
In emphysema, those elastic fibers break down. Inflammatory cells, recruited by cigarette smoke or other irritants, release enzymes that chew through the fibers and the structural scaffolding of the air sac walls. Without that scaffolding, neighboring air sacs rupture into each other, forming larger, floppy spaces. The result is a double problem: less surface area for gas exchange and less elastic recoil to push air out. Air gets trapped in the lungs, which is why people with emphysema often feel like they can’t fully exhale.
This destruction is permanent. Unlike an infection that heals, the lost tissue doesn’t grow back. The damage tends to progress over years, often silently at first, because the lungs have enough reserve capacity that you may not notice symptoms until a significant portion of the air sacs are gone.
How Emphysema Differs From Chronic Bronchitis
Chronic bronchitis, the other major COPD subtype, centers on the airways rather than the air sacs. The lining of the bronchial tubes becomes chronically inflamed and produces excessive mucus, leading to a persistent cough with phlegm on most days for at least three months in two consecutive years. The airflow limitation comes from swollen, narrowed airways rather than from destroyed air sacs.
Interestingly, the overlap is messier than textbooks suggest. Research comparing COPD patients with varying degrees of emphysema found that chronic bronchitis symptoms, specifically chronic cough and sputum production, were equally common regardless of how severe someone’s emphysema was. You can have terrible emphysema and still cough up mucus daily, or you can have mild emphysema with the same symptoms. One difference that did hold up: people with severe emphysema tended to have a lower body weight and reported worse quality of life scores than those with mild or no emphysema.
What Causes Emphysema
Cigarette smoking is by far the leading cause. The smoke triggers a flood of inflammatory cells into the lungs, and those cells release enzymes that degrade the elastic fibers holding the air sacs together. Long-term exposure to air pollution, chemical fumes, and dust can do the same thing on a smaller scale.
There is also a genetic form. Alpha-1 antitrypsin deficiency is an inherited condition in which the body doesn’t produce enough of a protein that normally protects the lungs from those destructive enzymes. Everyone inherits two copies of the gene, one from each parent. If both copies are mutated, you have the deficiency and face a much higher risk of developing emphysema, sometimes at a younger age and even without smoking. If you inherit one normal copy and one mutated copy, you’re a carrier and generally produce enough protective protein to avoid problems. The condition is most common in people of Northern European descent, but it can occur in anyone.
How Emphysema Is Detected
Spirometry confirms COPD but can’t distinguish emphysema from chronic bronchitis on its own. To actually see emphysema, doctors use a high-resolution CT scan. On these images, emphysema shows up as dark areas of low density where air sac walls have been destroyed.
The pattern on the scan can even reveal the subtype. The most common form, centrilobular emphysema, appears as small scattered dark spots in the center of the lung’s structural units, typically concentrated in the upper portions of the lungs. Panlobular emphysema, the type linked to alpha-1 antitrypsin deficiency, affects entire lung units more uniformly and tends to favor the lower lungs. A third type, paraseptal emphysema, shows up as a line of small cyst-like spaces along the outer edges of the lung, just beneath the chest wall.
These distinctions matter because they influence treatment decisions. For example, someone being evaluated for a procedure to reduce lung volume needs imaging that clearly shows which lobe is most severely affected.
How Emphysema Is Managed
Because emphysema falls under COPD, the core management is the same: inhaled medications to open the airways and reduce inflammation, pulmonary rehabilitation (a supervised exercise and education program), and, when needed, supplemental oxygen. Quitting smoking is the single most effective step for slowing further damage.
Where emphysema-specific treatment diverges is in advanced cases with severe air trapping. When the destroyed portions of lung are so overinflated that they compress healthier tissue, reducing the volume of those damaged areas can let the remaining lung expand and work better. This can be done surgically or through a less invasive bronchoscopic procedure using one-way valves placed inside the airways. The valves block air from entering the most damaged lobe, causing it to deflate over time.
Not everyone qualifies for these procedures. Candidates are typically people who remain significantly short of breath despite being on optimal medications, have completed pulmonary rehabilitation, and show severe hyperinflation on lung function testing. CT imaging needs to show a clear target lobe with the worst damage, and the person’s overall health has to be stable enough to tolerate the procedure. People with very frequent lung infections or certain other conditions are generally not eligible.
Why the Distinction Matters
In the U.S., about 3.8% of adults have been diagnosed with COPD, with women slightly more affected (4.1%) than men (3.4%). Within that group, the mix of emphysema and chronic bronchitis varies widely from person to person. Knowing which component dominates your COPD isn’t just academic. It shapes what imaging you need, whether you’re a candidate for lung volume reduction, and how aggressively your care team monitors for complications like collapsed lung segments or weight loss.
If you’ve been told you have COPD, it’s worth asking whether imaging has shown emphysema and, if so, how severe it is. That information gives both you and your care team a clearer picture of what’s driving your symptoms and which treatments are most likely to help.